H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Intellia Therapeutics (NTLA) with a Buy rating and $30 price target Intellia is a gene editing company developing medicines that utilize CRISPR/Cas9 technology, the analyst tells investors in a research note. The firm says the company’s NTLA-2002 provides a one-time option with comparable efficacy to prophylactic therapies. H.C. Wainwright believes the “dramatic” 2024 stock pullback presents a compelling opportunity to own Intellia ahead of 2025 catalysts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $50 from $90 at Truist
- Intellia Therapeutics: Promising Potential in Biotech with NTLA-2002 Advancements and Strategic Focus
- Positive Outlook on Intellia Therapeutics: Buy Rating Supported by Financial Performance and Sector Alignment
- Intellia Therapeutics’ Promising Future: Buy Rating Backed by Strong Financials and Program Advancements
- Buy/Sell: Wall Street’s top 10 stock calls this week